Press Releases

November 8, 2021

ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models

September 14, 2021

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

July 19, 2021

ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery

March 1, 2021

ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.

Reveal more

In the news

September 10, 2020

Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry

  |  MassBio

August 20, 2020

Four months after launch, Rome Therapeutics has hired a new chief scientist. Dennis Zaller, Ph.D., arrives at the startup from Celgene, where he spent five years overseeing partnerships with early-stage biotechs across immunology, fibrosis and immuno-oncology and ushering six new drugs into the clinic.  |  FIERCE Biotech

Reveal more